TITLE

Which antibiotic first in meningococcal disease? A national survey

AUTHOR(S)
Hudson, L.; Tickner, N.; Salt, P.
PUB. DATE
April 2011
SOURCE
Archives of Disease in Childhood -- Fetal & Neonatal Edition;Apr2011, Vol. 96 Issue 4, pe1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective Concerns over safety when using ceftriaxone in conjunction with calcium-containing solutions, despite administering these agents through different intravenous routes at different times,1 has led to cautions from regulatory bodies.2 3 The aim of the research was to survey all paediatric units in England and Wales to ascertain current guideline and antibiotic prescribing practices for treatment of suspected meningococcal disease. Methods In July 2009 an anonymous postal survey was sent to clinical leads of hospitals with resident acute paediatric services in England and Wales requesting information of first-line antibiotic policy for suspected meningococcal disease in children and infants. Results were collated in October 2009 and non-responding hospitals were checked for presence of a paediatric unit. In these hospitals, a consultant contact was sought and emailed a link to the same anonymous survey identical to the original. Final data was collated in November 2009. Results 223 hospitals were identified as having acute paediatric units, from which 170 (76%) responses were received. First-line antibiotic is closely split between ceftriaxone (82 units; 48%) and cefotaxime (76 units; 45%). Ninety-six (52%) units using ceftriaxone as first line (exclusively or as either cefotaxime or ceftriaxone) have no contraindications for using it in guidelines. Only 27% of units using ceftriaxone gave age-related contra-indications, with only 14% specifically advising against use in the under 3 month age group. The vast majority of units perceived that their guidelines were adhered to within their hospital, 84 saying always (49%) and 81 saying mostly (48%), however only 61 (36%) had conducted an audit. Conclusions First-line antibiotic choice is divided across England and Wales, with few units changing guidelines in response to the initial MHRA safety alert. Consequences of using intravenous calcium and ceftriaxone concomitantly are likely to be rare, but severe. Case reports1 of fatalities are small in number, are described in younger infants (less than 3 months) and in some cases at a significantly higher dosage of ceftriaxone than recommended by the UK product license and BNF-C. Ceftriaxone offers the advantage of a once daily administration allowing earlier ambulation and a theoretical reduction in drug error compared to the more frequently dosed cefotaxime. A compromise perhaps is found in those units who start with cefotaxime and swap to ceftriaxone if there are no contraindications. NICE guidance should provide some consistency. Over-riding this debate is the importance that any effective antibiotic is given as soon as possible in meningococcal disease and confusion about which drug should not cause delay in treatment.
ACCESSION #
61211363

 

Related Articles

  • Coadministration of the cyanobacterial lipopolysaccharide antagonist CyP with antibiotic inhibits cytokine production by an in vitro meningitis model infected with Neisseria meningitidis. Oliver, Rebecca; Staples, Karl J.; Heckels, John; Rossetti, Carlo; Molteni, Monica; Christodoulides, Myron // Journal of Antimicrobial Chemotherapy (JAC);May2012, Vol. 67 Issue 5, p1145 

    Objectives In this study, the objective was to determine the anti-inflammatory properties of CyP, a cyanobacterial lipopolysaccharide (LPS) antagonist, used in combination with antibiotic chemotherapy during infection of an in vitro meningitis model infected with Neisseria meningitidis...

  • Sporadic meningococcal disease in adults: Results of a... Stephens, David S.; Hajjeh, Rana A. // Annals of Internal Medicine;12/15/95, Vol. 123 Issue 12, p937 

    Presents an abstract of the study `Sporadic Meningococcal Disease in Adults: Results of a 5-Year Population-Based Study,' conducted by David S. Stephens, Rana A. Hajjeh et al. Methods; Results; Discussion.

  • Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Schneider, Muriel C.; Prosser, Beverly E.; Caesar, Joseph J. E.; Kugelberg, Elisabeth; Li, Su; Zhang, Qian; Quoraishi, Sadik; Lovett, Janet E.; Deane, Janet E.; Sim, Robert B.; Roversi, Pietro; Johnson, Steven; Tang, Christoph M.; Lea, Susan M. // Nature;4/16/2009, Vol. 458 Issue 7240, p890 

    The complement system is an essential component of the innate and acquired immune system, and consists of a series of proteolytic cascades that are initiated by the presence of microorganisms. In health, activation of complement is precisely controlled through membrane-bound and soluble...

  • Vaccines: Mix-and-match for meningitis.  // Nature;7/21/2011, Vol. 475 Issue 7356, p269 

    The article offers information on the research of Rino Rappuoli and colleagues at Novartis Vaccines and Diagnostics regarding the analysis of meningitis using Neisseria factor H binding protein (fHBP) sequence typing.

  • Meningococcal disease costly in children in Australia.  // PharmacoEconomics & Outcomes News;Jul2014, Vol. 707 Issue 1, p5 

    The article discusses research being done on the costs of meningococcal disease which references the study "The Inpatient Costs and Hospital Service Use Associated With Invasive Meningococcal Disease in South Australian Children," by B Wang and colleagues published in the July 3, 2014 issue of...

  • Secondhand smoke associated with invasive meningococcal disease.  // Infectious Disease News;Jan2011, Vol. 24 Issue 1, p8 

    The article focuses on a study by researchers from the Harvard School of Public Health which examined the association between exposure to secondhand smoke and invasive meningococcal disease.

  • Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-DT): A Multicenter, Open-label, Non-randomized, Phase III Clinical Trial. YADAV, SANGEETA; MANGLANI, M. V.; NARAYAN, D. H. ASHWATH; SHARMA, S.; RAVISH, H. S.; ARORA, R.; CASTELLS, V. BOSCH; ARYA, S.; OSTER, P. // Indian Pediatrics;Jun2014, Vol. 51 Issue 6, p451 

    Objective: To assess the safety and immunogenicity of a quadrivalent meningococcal (groups A,C,Y,W) polysaccharide diphtheria toxoid conjugate vaccine (MenACYW-DT) in India. Design: Open-label, descriptive, non-randomized study. Setting: Three medical college hospitals, one each in New Delhi,...

  • Meningococcal survivers exact sizeable burden in Spain.  // PharmacoEconomics & Outcomes News;Aug2014, Vol. 708 Issue 1, p7 

    The article discusses a research on meningococcal disease, in reference to the study "Costs of surviving meningococcal disease in Spain: Evaluation for two cases of severe meningitis and septicaemia," by J. Darba, et al., which appeared in the July 18, 2014 issue of "Vaccine."

  • Microbiology: RNAs at fever pitch. Narberhaus, Franz // Nature;10/10/2013, Vol. 502 Issue 7470, p178 

    The article focuses on Neisseria meningitidis, bacteria that causes meningitis which uses three different temperature sensing RNA molecules in evasion of immune response created due to rise in body temperature. It mentions that Neisseria meningitidis is a harmless human body resident bacterium...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics